Additionally, compared with ILC, IDC-L patients were significantly younger (>50: 69.8% vs 76.3%, P < 0.001, R = 0.073) and had smaller tumor size (>5 cm: 8.1% vs 13.3%, P < 0.001, R = 0.098), fewer positive lymph nodes (≥10: 8.1% vs 10.4%, P < 0.001, R = 0.053), higher rates of lumpectomy (53% vs 46.4%, P < 0.001, R = 0.069) and similar rates of ER and PR positivity (93.0% vs 95.0%, P < 0.001, R = 0.043; 80.9% vs 79.7%, P = 0.005, R = 0.015, respectively). This evidence concerns the gene ESR1 and neoplasm.